A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT07247110 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm

Interventions

DRUG: MK-4716
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Cetuximab

Sponsor

Merck Sharp & Dohme LLC